Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

Bobeck S Modjtahedi, 1–3 Tiffany Q Luong, 3 Stephan Chiu, 2 Tavé van Zyl, 4 Jane C Lin, 3 Donald S Fong 1–3 1Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, CA, USA; 2Department of Ophthalmology, Southern California Permanente Medical Grou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Modjtahedi BS, Luong TQ, Chiu S, van Zyl T, Lin JC, Fong DS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	age-related macular degeneration glaucoma aqueous suppressant pharmacology pharmacokinetics vascular endothelial growth factor intravitreal injection Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/423b1006c9b4488aa681449d6287ba2f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:423b1006c9b4488aa681449d6287ba2f
record_format	dspace
spelling	oai:doaj.org-article:423b1006c9b4488aa681449d6287ba2f2021-12-02T05:28:43ZTreatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives1177-5483https://doaj.org/article/423b1006c9b4488aa681449d6287ba2f2020-01-01T00:00:00Zhttps://www.dovepress.com/treatment-course-of-patients-with-exudative-age-related-macular-degene-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Bobeck S Modjtahedi, 1–3 Tiffany Q Luong, 3 Stephan Chiu, 2 Tavé van Zyl, 4 Jane C Lin, 3 Donald S Fong 1–3 1Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, CA, USA; 2Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, CA, USA; 3Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA; 4Glaucoma Service, Massachusetts Eye and Ear Infirmary, Boston, MA, USACorrespondence: Bobeck S ModjtahediEye Monitoring Center, Kaiser Permanente Southern California, 1011 Baldwin Park Blvd, Baldwin Park, CA 91706, USAEmail BobModj@gmail.comPurpose: To characterize the visual outcomes and the treatment course of patients with exudative age-related macular degeneration (AMD) based on ocular hypotensive use.Design: A matched retrospective cohort study of patients enrolled in Kaiser Permanente Southern California health plan was conducted. Patients taking ocular hypotensives were identified using pharmacy dispensing data and were matched to controls to compare visual acuity, number of anti-VEGF injections, and conversation to secondary anti-VEGF agents in the first year of treatment. Subgroup analysis was performed based on the number of ocular hypotensive agents (0, 1, 2 or 3+ agents) and drug class (aqueous suppressants and prostaglandin analogs).Results: A total of 234 patients patients were examined. Baseline and final visual acuity did not significantly differ between drop users and controls, including on subgroup analysis. The average number of anti-VEGF injections did not differ between drop users and controls (6.1 vs 6.2, p=0.97), nor did the percentage of patients who were switched to a second-line anti-VEGF agent (23.9% vs 17.9%, p=0.26). Subgroup analysis did not reveal significant differences in the number of anti-VEGF injections and the percentage of patients switched to secondary agents, with patients receiving 6 ± 1 injections across regardless of the number or class of ocular hypotensive agents used.Conclusion: Patients with concurrent glaucoma and exudative AMD have similar visual outcomes and treatment courses compared to those not taking ocular hypotensives. Although aqueous suppressants have been suggested to prolong anti-VEGF residence time, patients using these agents did not demonstrate visual benefit or a reduced injection burden in this series.Keywords: age-related macular degeneration, bevacizumab, glaucoma, aqueous suppressant, pharmacology, pharmacokinetics, vascular endothelial growth factor, intravitreal injectionModjtahedi BSLuong TQChiu Svan Zyl TLin JCFong DSDove Medical Pressarticleage-related macular degenerationglaucomaaqueous suppressantpharmacologypharmacokineticsvascular endothelial growth factorintravitreal injectionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 187-195 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration glaucoma aqueous suppressant pharmacology pharmacokinetics vascular endothelial growth factor intravitreal injection Ophthalmology RE1-994
spellingShingle	age-related macular degeneration glaucoma aqueous suppressant pharmacology pharmacokinetics vascular endothelial growth factor intravitreal injection Ophthalmology RE1-994 Modjtahedi BS Luong TQ Chiu S van Zyl T Lin JC Fong DS Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
description	Bobeck S Modjtahedi, 1–3 Tiffany Q Luong, 3 Stephan Chiu, 2 Tavé van Zyl, 4 Jane C Lin, 3 Donald S Fong 1–3 1Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, CA, USA; 2Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, CA, USA; 3Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA; 4Glaucoma Service, Massachusetts Eye and Ear Infirmary, Boston, MA, USACorrespondence: Bobeck S ModjtahediEye Monitoring Center, Kaiser Permanente Southern California, 1011 Baldwin Park Blvd, Baldwin Park, CA 91706, USAEmail BobModj@gmail.comPurpose: To characterize the visual outcomes and the treatment course of patients with exudative age-related macular degeneration (AMD) based on ocular hypotensive use.Design: A matched retrospective cohort study of patients enrolled in Kaiser Permanente Southern California health plan was conducted. Patients taking ocular hypotensives were identified using pharmacy dispensing data and were matched to controls to compare visual acuity, number of anti-VEGF injections, and conversation to secondary anti-VEGF agents in the first year of treatment. Subgroup analysis was performed based on the number of ocular hypotensive agents (0, 1, 2 or 3+ agents) and drug class (aqueous suppressants and prostaglandin analogs).Results: A total of 234 patients patients were examined. Baseline and final visual acuity did not significantly differ between drop users and controls, including on subgroup analysis. The average number of anti-VEGF injections did not differ between drop users and controls (6.1 vs 6.2, p=0.97), nor did the percentage of patients who were switched to a second-line anti-VEGF agent (23.9% vs 17.9%, p=0.26). Subgroup analysis did not reveal significant differences in the number of anti-VEGF injections and the percentage of patients switched to secondary agents, with patients receiving 6 ± 1 injections across regardless of the number or class of ocular hypotensive agents used.Conclusion: Patients with concurrent glaucoma and exudative AMD have similar visual outcomes and treatment courses compared to those not taking ocular hypotensives. Although aqueous suppressants have been suggested to prolong anti-VEGF residence time, patients using these agents did not demonstrate visual benefit or a reduced injection burden in this series.Keywords: age-related macular degeneration, bevacizumab, glaucoma, aqueous suppressant, pharmacology, pharmacokinetics, vascular endothelial growth factor, intravitreal injection
format	article
author	Modjtahedi BS Luong TQ Chiu S van Zyl T Lin JC Fong DS
author_facet	Modjtahedi BS Luong TQ Chiu S van Zyl T Lin JC Fong DS
author_sort	Modjtahedi BS
title	Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
title_short	Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
title_full	Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
title_fullStr	Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
title_full_unstemmed	Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
title_sort	treatment course of patients with exudative age-related macular degeneration using ocular hypotensives
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/423b1006c9b4488aa681449d6287ba2f
work_keys_str_mv	AT modjtahedibs treatmentcourseofpatientswithexudativeagerelatedmaculardegenerationusingocularhypotensives AT luongtq treatmentcourseofpatientswithexudativeagerelatedmaculardegenerationusingocularhypotensives AT chius treatmentcourseofpatientswithexudativeagerelatedmaculardegenerationusingocularhypotensives AT vanzylt treatmentcourseofpatientswithexudativeagerelatedmaculardegenerationusingocularhypotensives AT linjc treatmentcourseofpatientswithexudativeagerelatedmaculardegenerationusingocularhypotensives AT fongds treatmentcourseofpatientswithexudativeagerelatedmaculardegenerationusingocularhypotensives
_version_	1718400348637364224

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

Ejemplares similares